Mette Vesterhus

  • Professor; MD, PhD

Education

PhD University of Bergen, 2009

MD University of Bergen, 1999

Norwegian clinical specialist accreditations

"Indremedisin" (Internal medicine), "Fordøyelsessykdommer" (Gastroenterology)

Current and recent positions

2018-present: Associate Professor (50%), University of Bergen

2018-present: Senior consultant, Haraldsplass Deaconess Hospital, Bergen

2016-present: Group leader, Clinical group Bergen, Norwegian PSC Research Center, OUH Rikshospitalet

2012-2018: Post.doc., Norwegian PSC Research Center, OUH Rikshospitalet and National Center of Excellence for Ultrasound in Gastroenterology, Dept. of Medicine, Haukeland University Hospital, Bergen

2009-2017: Clinical fellow in gastroenterology (50%), Dept. of Medicine, Haukeland University Hospital, Bergen

2006-2007: Visiting PhD Research fellow (12 months), Harvard Medical School, Boston, USA

Research interest

Primary sclerosing cholangitis. Biomarkers of disease activity and prognosis. Liver fibrosis.  Elastography. Imaging in PSC. Prospective cohorts. Clinical trials.

 

 

Publications 2023

Braadland PR, Bergquist A, Kummen M, Bossen L, Engesæter LK, Reims HM, Björk I, Grzyb K, Abildgaard A, Småstuen MC, Folseraas T, Trøseid M, Ulvik A, Ueland PM, Melum E, Line PD, Høivik ML, Grønbæk H, Karlsen TH, Vesterhus M, Hov JR (2023)
Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation
J Hepatol, 79 (4), 955-966
DOI 10.1016/j.jhep.2023.05.038, PubMed 37328069

Helgadottir H, Folseraas T, Kemmerich G, Aabakken L, Jørgensen KK, Vesterhus M (2023)
[Not Available]
Tidsskr Nor Laegeforen, 143 (17)
DOI 10.4045/tidsskr.23.0156, PubMed 37987062

Helgadottir H, Vesterhus M (2023)
Noninvasive evaluation of fibrosis in adult biliary diseases
Curr Opin Gastroenterol, 39 (2), 83-88
DOI 10.1097/MOG.0000000000000909, PubMed 36821455

Lapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud MM, Schramm C, Arbelaiz A, O'Rourke CJ, La Casta A, Milkiewicz M, Pastor T, Vesterhus M, Jimenez-Agüero R, Dill MT, Lamarca A, Valle JW, Macias RIR, Izquierdo-Sanchez L, Pérez Castaño Y, Caballero-Camino FJ, Riaño I, Krawczyk M, Ibarra C, Bustamante J et al. (2023)
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
J Hepatol, 79 (1), 93-108
DOI 10.1016/j.jhep.2023.02.027, PubMed 36868481

Wacker EM, Uellendahl-Werth F, Bej S, Wolkenhauer O, Vesterhus M, Lieb W, Franke A, Karlsen TH, Folseraas T, Ellinghaus D (2023)
Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis
JHEP Rep, 6 (2), 100988
DOI 10.1016/j.jhepr.2023.100988, PubMed 38304234

Publications 2022

Bergquist A, Weismüller TJ, Levy C, Rupp C, Joshi D, Nayagam JS, Montano-Loza AJ, Lytvyak E, Wunsch E, Milkiewicz P, Zenouzi R, Schramm C, Cazzagon N, Floreani A, Liby IF, Wiestler M, Wedemeyer H, Zhou T, Strassburg CP, Rigopoulou E, Dalekos G, Narasimman M, Verhelst X, Degroote H, Vesterhus M et al. (2022)
Impact on follow-up strategies in patients with primary sclerosing cholangitis
Liver Int, 43 (1), 127-138
DOI 10.1111/liv.15286, PubMed 35535655

Braadland PR, Schneider KM, Bergquist A, Molinaro A, Lövgren-Sandblom A, Henricsson M, Karlsen TH, Vesterhus M, Trautwein C, Hov JR, Marschall HU (2022)
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis
JHEP Rep, 4 (11), 100561
DOI 10.1016/j.jhepr.2022.100561, PubMed 36176935

Helgadottir H, Folvik G, Vesterhus M (2022)
Improvement of cholestatic episodes in patients with benign recurrent intrahepatic cholestasis (BRIC) treated with rifampicin. A long-term follow-up
Scand J Gastroenterol, 58 (5), 512-520
DOI 10.1080/00365521.2022.2143725, PubMed 36369734

Laursen TL, Bossen L, Pihl R, Troldborg A, Sandahl TD, Hansen AG, Folserass T, Vesterhus M, Grønbæk H, Thiel S (2022)
Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases
J Clin Transl Hepatol, 10 (5), 796-802
DOI 10.14218/JCTH.2021.00515, PubMed 36304505

Singh Y, Jons WA, Eaton JE, Vesterhus M, Karlsen T, Bjoerk I, Abildgaard A, Jorgensen KK, Folseraas T, Little D, Gulamhusein AF, Petrovic K, Negard A, Conte GM, Sobek JD, Jagtap J, Venkatesh SK, Gores GJ, LaRusso NF, Lazaridis KN, Erickson BJ (2022)
Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis
Eur Radiol Exp, 6 (1), 58
DOI 10.1186/s41747-022-00312-x, PubMed 36396865

Vesterhus M (2022)
[Good TIPS for severe liver disease]
Tidsskr Nor Laegeforen, 142 (14)
DOI 10.4045/tidsskr.22.0585, PubMed 36226424

Vesterhus M, Jørgensen KK, Frigstad SO, Haukeland JW, Karlsen TH (2022)
[We need a new strategy for liver disease]
Tidsskr Nor Laegeforen, 142 (3)
DOI 10.4045/tidsskr.21.0892, PubMed 35170917

Publications 2021

Bossen L, Vesterhus M, Hov JR, Färkkilä M, Rosenberg WM, Møller HJ, Boberg KM, Karlsen TH, Grønbæk H (2021)
Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis
Clin Transl Gastroenterol, 12 (3), e00315
DOI 10.14309/ctg.0000000000000315, PubMed 33646203

Dhillon AK, Rupp C, Bergquist A, Voitl R, Folseraas T, Trøseid M, Midttun Ø, Ueland PM, Karlsen TH, Vesterhus M, Kummen M, Hov JR (2021)
Associations of neopterin and kynurenine-tryptophan ratio with survival in primary sclerosing cholangitis
Scand J Gastroenterol, 56 (4), 443-452
DOI 10.1080/00365521.2021.1880627, PubMed 33583308

Fossdal G, Mjelle AB, Wiencke K, Bjørk I, Gilja OH, Folseraas T, Karlsen TH, Rosenberg W, Giil LM, Vesterhus M (2021)
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF
JHEP Rep, 3 (5), 100328
DOI 10.1016/j.jhepr.2021.100328, PubMed 34485881

Mjelle AB, Mulabecirovic A, Olafsdottir EJ, Gilja OH, Havre RF, Vesterhus M (2021)
Controlled Attenuation Parameter in Healthy Individuals Aged 8-70 Years
Ultrasound Int Open, 7 (1), E6-E13
DOI 10.1055/a-1461-4714, PubMed 33969259

Vesterhus M, Wiencke K, Haukeland JW, Frigstad SO, Karlsen LN, Jørgensen KK, Folseraas T (2021)
[Diagnosis and treatment of autoimmune hepatitis]
Tidsskr Nor Laegeforen, 141 (10)
DOI 10.4045/tidsskr.20.1045, PubMed 34182737

Publications 2020

Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, Nogueira NF, Bowlus CL, Gotlieb N, Shibolet O, Lynch KD, Chapman RW, Rupp C, Vesterhus M, Jørgensen KK, Rorsman F et al. (2020)
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 18 (10), 2295-2304.e2
DOI 10.1016/j.cgh.2020.02.014, PubMed 32068151

Kummen M, Thingholm LB, Rühlemann MC, Holm K, Hansen SH, Moitinho-Silva L, Liwinski T, Zenouzi R, Storm-Larsen C, Midttun Ø, McCann A, Ueland PM, Høivik ML, Vesterhus M, Trøseid M, Laudes M, Lieb W, Karlsen TH, Bang C, Schramm C, Franke A, Hov JR (2020)
Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis
Gastroenterology, 160 (5), 1784-1798.e0
DOI 10.1053/j.gastro.2020.12.058, PubMed 33387530

Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D, Manns MP, Vesterhus M, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), International Autoimmune Hepatitis Group (IAIHG) (2020)
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group
J Hepatol, 73 (6), 1496-1506
DOI 10.1016/j.jhep.2020.07.023, PubMed 32707224

Lohse AW, Sebode M, Vesterhus M (2020)
Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"
J Hepatol, 74 (3), 755-756
DOI 10.1016/j.jhep.2020.11.031, PubMed 33309116

Mjelle AB, Fossdal G, Gilja OH, Vesterhus M (2020)
Liver Elastography in Primary Sclerosing Cholangitis Patients Using Three Different Scanner Systems
Ultrasound Med Biol, 46 (8), 1854-1864
DOI 10.1016/j.ultrasmedbio.2020.03.025, PubMed 32507342

Mjelle AB, Mulabecirovic A, Havre RF, Olafsdottir EJ, Gilja OH, Vesterhus M (2020)
Liver Elastography in Healthy Children Using Three Different Systems - How Many Measurements Are Necessary?
Ultraschall Med, 43 (5), 488-497
DOI 10.1055/a-1283-5906, PubMed 33348414

Taraldsen V, Tomasgard S, Rudlang M, Gilja O, Vesterhus M, Mjelle A (2020)
Point Shear Wave Elastography and the Effect of Physical Exercise, Alcohol Consumption, and Respiration in Healthy Adults
Ultrasound Int Open, 6 (3), E54-E61
DOI 10.1055/a-1298-9642, PubMed 33305164

Taraldsen V, Tomasgard S, Rudlang MT, Gilja OH, Vesterhus M, Mjelle AB (2020)
Correction: Point Shear Wave Elastography and the Effect of Physical Exercise, Alcohol Consumption, and Respiration in Healthy Adults
Ultrasound Int Open, 6 (3), E66
DOI 10.1055/a-1340-1260, PubMed 33426423

Vesterhus M, Karlsen TH (2020)
Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities
J Gastroenterol, 55 (6), 588-614
DOI 10.1007/s00535-020-01681-z, PubMed 32222826

Vesterhus M, Nielsen MJ, Hov JR, Saffioti F, Manon-Jensen T, Leeming DJ, Moum B, Boberg KM, Pinzani M, Karlsen TH, Karsdal MA, Thorburn D (2020)
Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease
JHEP Rep, 3 (1), 100178
DOI 10.1016/j.jhepr.2020.100178, PubMed 33225252

Publications 2019

Dhillon AK, Kremer AE, Kummen M, Boberg KM, Elferink RPO, Karlsen TH, Beuers U, Vesterhus M, Hov JR (2019)
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis
Sci Rep, 9 (1), 8450
DOI 10.1038/s41598-019-44762-7, PubMed 31186435

Mjelle AB, Mulabecirovic A, Havre RF, Rosendahl K, Juliusson PB, Olafsdottir E, Gilja OH, Vesterhus M (2019)
Normal Liver Stiffness Values in Children: A Comparison of Three Different Elastography Methods
J Pediatr Gastroenterol Nutr, 68 (5), 706-712
DOI 10.1097/MPG.0000000000002320, PubMed 30889132

Saffioti F, Roccarina D, Vesterhus M, Hov JR, Rosenberg W, Pinzani M, Pereira SP, Boberg KM, Thorburn D (2019)
Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis
Eur J Clin Invest, 49 (5), e13088
DOI 10.1111/eci.13088, PubMed 30762236

Publications 2018

Dhillon AK, Kummen M, Trøseid M, Åkra S, Liaskou E, Moum B, Vesterhus M, Karlsen TH, Seljeflot I, Hov JR (2018)
Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis
Liver Int, 39 (2), 371-381
DOI 10.1111/liv.13979, PubMed 30269440

Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN (2018)
Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning
Hepatology, 71 (1), 214-224
DOI 10.1002/hep.30085, PubMed 29742811

Mulabecirovic A, Mjelle AB, Gilja OH, Vesterhus M, Havre RF (2018)
Repeatability of shear wave elastography in liver fibrosis phantoms-Evaluation of five different systems
PLoS One, 13 (1), e0189671
DOI 10.1371/journal.pone.0189671, PubMed 29293527

Mulabecirovic A, Mjelle AB, Gilja OH, Vesterhus M, Havre RF (2018)
Liver elasticity in healthy individuals by two novel shear-wave elastography systems-Comparison by age, gender, BMI and number of measurements
PLoS One, 13 (9), e0203486
DOI 10.1371/journal.pone.0203486, PubMed 30216377

Nielsen MJ, Thorburn D, Leeming DJ, Hov JR, Nygård S, Moum B, Saffioti F, Gilja OH, Boberg KM, Mazza G, Røsjø H, Pinzani M, Karlsen TH, Karsdal MA, Vesterhus M (2018)
Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis
Aliment Pharmacol Ther, 48 (2), 179-189
DOI 10.1111/apt.14806, PubMed 29851098

Publications 2017

Bende F, Mulabecirovic A, Sporea I, Popescu A, Sirli R, Gilja OH, Vesterhus M, Havre RF (2017)
Assessing Liver Stiffness by 2-D Shear Wave Elastography in a Healthy Cohort
Ultrasound Med Biol, 44 (2), 332-341
DOI 10.1016/j.ultrasmedbio.2017.10.013, PubMed 29249457

de Vries EMG, Färkkilä M, Milkiewicz P, Hov JR, Eksteen B, Thorburn D, Chazouillères O, Pares A, Nygård S, Gilja OH, Wunsch E, Invernizzi P, Carbone M, Bernuzzi F, Boberg KM, Røsjø H, Rosenberg W, Beuers UH, Ponsioen CY, Karlsen TH, Vesterhus M (2017)
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study
Liver Int, 37 (10), 1554-1561
DOI 10.1111/liv.13402, PubMed 28267887

Karlsen TH, Folseraas T, Thorburn D, Vesterhus M (2017)
Primary sclerosing cholangitis - a comprehensive review
J Hepatol, 67 (6), 1298-1323
DOI 10.1016/j.jhep.2017.07.022, PubMed 28802875

Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, Thorbjørnsen LW, Paulsen V, Lundin K, Dale I, Gilja OH, Zweers SJLB, Vatn M, Schaap FG, Jansen PLM, Ueland T, Røsjø H, Moum B, Ponsioen CY, Boberg KM, Färkkilä M, Karlsen TH, Lund-Johansen F (2017)
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis
J Hepatol, 66 (6), 1214-1222
DOI 10.1016/j.jhep.2017.01.019, PubMed 28161472

Publications 2016

Hov JR, Boberg KM, Taraldsrud E, Vesterhus M, Boyadzhieva M, Solberg IC, Schrumpf E, Vatn MH, Lie BA, Molberg Ø, Karlsen TH (2016)
Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis
Liver Int, 37 (3), 458-465
DOI 10.1111/liv.13238, PubMed 27558072

Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, Weiss KH, Liaskou E, Vesterhus M, Karlsen TH, Mindorf S, Schemmer P, Bär F, Teegen B, Schröder T, Ehlers M, Hammers CM, Komorowski L, Lehnert H, Fellermann K, Derer S, Hov JR, Sina C (2016)
Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis
Gut, 66 (1), 137-144
DOI 10.1136/gutjnl-2016-311739, PubMed 27406039

Jørgensen SF, Trøseid M, Kummen M, Anmarkrud JA, Michelsen AE, Osnes LT, Holm K, Høivik ML, Rashidi A, Dahl CP, Vesterhus M, Halvorsen B, Mollnes TE, Berge RK, Moum B, Lundin KE, Fevang B, Ueland T, Karlsen TH, Aukrust P, Hov JR (2016)
Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation
Mucosal Immunol, 9 (6), 1455-1465
DOI 10.1038/mi.2016.18, PubMed 26982597

Kummen M, Holm K, Anmarkrud JA, Nygård S, Vesterhus M, Høivik ML, Trøseid M, Marschall HU, Schrumpf E, Moum B, Røsjø H, Aukrust P, Karlsen TH, Hov JR (2016)
The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls
Gut, 66 (4), 611-619
DOI 10.1136/gutjnl-2015-310500, PubMed 26887816

Kummen M, Vesterhus M, Trøseid M, Moum B, Svardal A, Boberg KM, Aukrust P, Karlsen TH, Berge RK, Hov JR (2016)
Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function
United European Gastroenterol J, 5 (4), 532-541
DOI 10.1177/2050640616663453, PubMed 28588885

Mjelle AB, Mulabecirovic A, Hausken T, Havre RF, Gilja OH, Vesterhus M (2016)
Ultrasound and Point Shear Wave Elastography in Livers of Patients with Primary Sclerosing Cholangitis
Ultrasound Med Biol, 42 (9), 2146-55
DOI 10.1016/j.ultrasmedbio.2016.04.016, PubMed 27262519

Mulabecirovic A, Vesterhus M, Gilja OH, Havre RF (2016)
In Vitro Comparison of Five Different Elastography Systems for Clinical Applications, Using Strain and Shear Wave Technology
Ultrasound Med Biol, 42 (11), 2572-2588
DOI 10.1016/j.ultrasmedbio.2016.07.002, PubMed 27570209

Vesterhus M, Melum E (2016)
Prognostic biomarkers and surrogate end points in PSC
Liver Int, 36 (12), 1748-1751
DOI 10.1111/liv.13216, PubMed 27864874

Zweers SJ, Shiryaev A, Komuta M, Vesterhus M, Hov JR, Perugorria MJ, de Waart DR, Chang JC, Tol S, Te Velde AA, de Jonge WJ, Banales JM, Roskams T, Beuers U, Karlsen TH, Jansen PL, Schaap FG (2016)
Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis
Liver Int, 36 (9), 1370-7
DOI 10.1111/liv.13092, PubMed 26866350

Publications 2015

Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygård S, Godang K, Andersen IM, Naess S, Thorburn D, Saffioti F, Vatn M, Gilja OH, Lund-Johansen F, Syversveen T, Brabrand K, Parés A, Ponsioen CY, Pinzani M, Färkkilä M, Moum B, Ueland T, Røsjø H, Rosenberg W, Boberg KM, Karlsen TH (2015)
Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Hepatology, 62 (1), 188-97
DOI 10.1002/hep.27825, PubMed 25833813

Publications 2013

Karlsen TH, Vesterhus M, Boberg KM (2013)
Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis
Aliment Pharmacol Ther, 39 (3), 282-301
DOI 10.1111/apt.12581, PubMed 24372568

Ræder H, McAllister FE, Tjora E, Bhatt S, Haldorsen I, Hu J, Willems SM, Vesterhus M, El Ouaamari A, Liu M, Ræder MB, Immervoll H, Hoem D, Dimcevski G, Njølstad PR, Molven A, Gygi SP, Kulkarni RN (2013)
Carboxyl-ester lipase maturity-onset diabetes of the young is associated with development of pancreatic cysts and upregulated MAPK signaling in secretin-stimulated duodenal fluid
Diabetes, 63 (1), 259-69
DOI 10.2337/db13-1012, PubMed 24062244

Ræder H, Vesterhus M, El Ouaamari A, Paulo JA, McAllister FE, Liew CW, Hu J, Kawamori D, Molven A, Gygi SP, Njølstad PR, Kahn CR, Kulkarni RN (2013)
Absence of diabetes and pancreatic exocrine dysfunction in a transgenic model of carboxyl-ester lipase-MODY (maturity-onset diabetes of the young)
PLoS One, 8 (4), e60229
DOI 10.1371/journal.pone.0060229, PubMed 23565203

Publications 2011

Haldorsen IS, Ræder H, Vesterhus M, Molven A, Njølstad PR (2011)
The role of pancreatic imaging in monogenic diabetes mellitus
Nat Rev Endocrinol, 8 (3), 148-59
DOI 10.1038/nrendo.2011.197, PubMed 22124438

Johansson BB, Torsvik J, Bjørkhaug L, Vesterhus M, Ragvin A, Tjora E, Fjeld K, Hoem D, Johansson S, Ræder H, Lindquist S, Hernell O, Cnop M, Saraste J, Flatmark T, Molven A, Njølstad PR (2011)
Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease
J Biol Chem, 286 (40), 34593-605
DOI 10.1074/jbc.M111.222679, PubMed 21784842

Publications 2010

Vesterhus M, Raeder H, Kurpad AJ, Kawamori D, Molven A, Kulkarni RN, Kahn CR, Njølstad PR (2010)
Pancreatic function in carboxyl-ester lipase knockout mice
Pancreatology, 10 (4), 467-76
DOI 10.1159/000266284, PubMed 20720448

Publications 2008

Haldorsen IS, Vesterhus M, Raeder H, Jensen DK, Søvik O, Molven A, Njølstad PR (2008)
Lack of pancreatic body and tail in HNF1B mutation carriers
Diabet Med, 25 (7), 782-7
DOI 10.1111/j.1464-5491.2008.02460.x, PubMed 18644064

Vesterhus M, Haldorsen IS, Raeder H, Molven A, Njølstad PR (2008)
Reduced pancreatic volume in hepatocyte nuclear factor 1A-maturity-onset diabetes of the young
J Clin Endocrinol Metab, 93 (9), 3505-9
DOI 10.1210/jc.2008-0340, PubMed 18593771

Vesterhus M, Raeder H, Aurlien H, Gjesdal CG, Bredrup C, Holm PI, Molven A, Bindoff L, Berstad A, Njølstad PR (2008)
Neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to CEL mutations
Diabetes Care, 31 (9), 1738-40
DOI 10.2337/dc07-2217, PubMed 18544793

Publications 2007

Vesterhus M, Raeder H, Johansson S, Molven A, Njølstad PR (2007)
Pancreatic exocrine dysfunction in maturity-onset diabetes of the young type 3
Diabetes Care, 31 (2), 306-10
DOI 10.2337/dc07-1002, PubMed 17989309

Page visits: 10569